نتایج جستجو برای: naproxen

تعداد نتایج: 2312  

Journal: :Reumatologia clinica 2014
Margarita Capel Jesús Tornero José Luis Zamorano Itziar Oyagüez Miguel Ángel Casado Joaquín Sánchez-Covisa Angel Lanas

OBJECTIVE To assess, from the perspective of the National Healthcare System, the efficiency of a fixed-dose combination of naproxen and esomeprazole (naproxen/esomeprazole) in the treatment of osteoarthritis (OA) compared to other NSAID, alone or in combination with a proton pump inhibitor (PPI). METHODS A Markov model was used; it included different health states defined by gastrointestinal ...

2003

Effectiveness of naproxen suppositories on ambulation was studied following laparoscopic sterilization. In a double-blinded randomized placebo study, 20 patients received 500 mg naproxen suppositories and 20 patients placebo suppositories. Postoperatively 10 naproxen patients and 11 placebo patients reported high pain scores, indicating severe pain and requiring opiates. Times to reach street f...

Journal: :Polish journal of microbiology 2016
Danuta Wojcieszyńska Dorota Domaradzka Katarzyna Hupert-Kocurek Urszula Guzik

Naproxen is a one of the most popular non-steroidal anti-inflammatory drugs (NSAIDs) entering the environment as a result of high consumption. For this reason, there is an emerging need to recognize mechanisms of its degradation and enzymes engaged in this process. Planococcus sp. S5 is a gram positive strain able to degrade naproxen in monosubstrate culture (27%). However, naproxen is not a su...

2017
Mohammad Najlah Sally Freeman Mouhamad Khoder David Attwood

The present study compares the use of high generation G3 and low generation G0 Polyamidoamine (PAMAM) dendrimers as drug carriers of naproxen (NAP), a poorly water soluble drug. Naproxen was conjugated to G3 in different ratios and to G0 in a 1:1 ratio via a diethylene glycol linker. A lauroyl chain (L), a lipophilic permeability enhancer, was attached to G3 and G0 prodrugs. The G3 and G0 conju...

Journal: :Molbank 2021

The title compound was obtained in high yield the reaction between tryptamine and naproxen. newly synthesized naproxen derivative fully analyzed characterized via 1H, 13C-NMR, UV, IR, mass spectral data.

2010
Rajendra Nagar

The present research has been undertaken with the aim to develop a transdermal gel formulation of naproxen, which would attenuate the gastrointestinal related toxicities associated with oral administration. The potential gastrointestinal disorders associated with oral administration of naproxen (NSAID’s) can be avoided by delivering the drug to the inflammation site. Gel based formulations are ...

2015
Bogdan Tarus Hélène Bertrand Gloria Zedda Carmelo Di Primo Stéphane Quideau Anny Slama-Schwok

The nucleoprotein (NP) binds the viral RNA genome as oligomers assembled with the polymerase in a ribonucleoprotein complex required for transcription and replication of influenza A virus. Novel antiviral candidates targeting the nucleoprotein either induced higher order oligomers or reduced NP oligomerization by targeting the oligomerization loop and blocking its insertion into adjacent nucleo...

2015
Dorota Domaradzka Urszula Guzik Katarzyna Hupert-Kocurek Danuta Wojcieszyńska

Naproxen is a non-steroidal anti-inflammatory drug frequently detected in the influent and effluent of sewage treatment plants. The Gram-positive strain Planococcus sp. S5 was able to remove approximately 30 % of naproxen after 35 days of incubation in monosubstrate culture. Under cometabolic conditions, with glucose or phenol as a growth substrate, the degradation efficiency of S5 increased. D...

Journal: :Annals of the rheumatic diseases 2007
J Y Reginster K Malmstrom A Mehta G Bergman A T Ko S P Curtis A S Reicin

OBJECTIVES To assess the efficacy and safety of etoricoxib 60 mg once daily and naproxen 500 mg twice daily over a 138-week treatment period in patients with osteoarthritis (OA). METHODS Two 1-year randomised, double blind, parallel group two-part base studies (part I 12 weeks; part II 40 weeks), followed by an 86-week extension, in patients with OA (hip or knee) were conducted at 80 clinical...

Journal: :British journal of clinical pharmacology 2007
Dagmar Kubitza Michael Becka Wolfgang Mueck Michael Zuehlsdorf

AIMS Rivaroxaban (BAY 59-7939) is in advanced clinical development for the prevention and treatment of thromboembolic disorders. Frequent co-medications in the patient populations likely to receive rivaroxaban include NSAIDs. This randomized, two-way crossover study, with a naproxen run-in period, was performed to determine whether naproxen influences the tolerability, pharmacodynamics and phar...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید